Human RELB (Rel B) knockout HeLa cell lysate
Be the first to review this product! Submit a review
|
(0 Publication)
RELB KO cell lysate available now. KO validated by Western blot. Free of charge wild type control included. Knockout achieved by using CRISPR/Cas9, Homozygous: 65 bp deletion in exon4.
View Alternative Names
I-Rel, Nuclear factor of kappa light polypeptide gene enhancer in B-cells 3, RELB_HUMAN, Reticuloendotheliosis viral oncogene homolog B, Transcription factor Rel B, v rel avian reticuloendotheliosis viral oncogene homolog B, v rel reticuloendotheliosis viral oncogene homolog B
- WB
Lab
Western blot - Human RELB (Rel B) knockout HeLa cell lysate (AB257635)
Lane 1 : Wild-type HeLa cell lysate (40µg)
Lane 2 : RELB knockout HeLa cell lysate (40µg)
Lane 3 : Raji cell lysate (40µg)
Lane 4 : LnCap cell lysate (40µg)
Lanes 1- 4 : Merged signal (red and green). Green - ab33907 observed at 70 kDa. Red - loading control, ab8245 observed at 37 kDa.
ab33907 Anti-Rel B antibody [EP614Y] was shown to specifically react with Rel B in wild-type HeLa cells in western blot. Loss of signal was observed when knockout cell line ab265948 (knockout cell lysate ab257635) was used. Wild-type and Rel B knockout samples were subjected to SDS-PAGE. ab33907 and Anti-GAPDH antibody [6C5] - Loading Control (ab8245) were incubated overnight at 4°C at 1 in 1000 and 1 in 20000 dilution respectively. Blots were developed with Goat anti-Rabbit IgG H&L (IRDye® 800CW) preadsorbed (ab216773) and Goat anti-Mouse IgG H&L (IRDye® 680RD) preadsorbed (ab216776) secondary antibodies at 1 in 20000 dilution for 1 hour at room temperature before imaging.
All lanes:
Western blot - Anti-Rel B antibody [EP614Y] (<a href='/en-us/products/primary-antibodies/rel-b-antibody-ep614y-ab33907'>ab33907</a>) at 1/1000 dilution
Lane 1:
Wild-type HeLa cell lysate at 40 µg
Lane 2:
RELB knockout HeLa cell lysate at 40 µg
Lane 2:
Western blot - Human RELB (Rel B) knockout HeLa cell line (<a href='/en-us/products/cell-lines/human-relb-rel-b-knockout-hela-cell-line-ab265948'>ab265948</a>)
Lane 3:
Raji cell lysate at 40 µg
Lane 4:
LnCap cell lysate at 40 µg
Predicted band size: 62 kDa
Observed band size: 70 kDa
false
- Sanger seq
Unknown
Sanger Sequencing - Human RELB (Rel B) knockout HeLa cell lysate (AB257635)
Homozygous : 65 bp deletion in exon4
Reactivity data
Product details
Knockout cell lysate achieved by CRISPR/Cas9.
REACH authorisation
Abcam has not and does not intend to apply for the REACH Authorisation of customers' uses of products that contain European Authorisation list (Annex XIV) substances.
It is the responsibility of our customers to check the necessity of application of REACH Authorisation, and any other relevant authorisations, for their intended uses.
Lysate preparation: Our lysates are made using RIPA buffer to which we add a protease inhibitor cocktail and phosphatase inhibitor cocktail (ratio: 300:100:10). This means that the protein of interest is denatured. If you require a native form of the protein please use the live cell version. Please refer to our lysis protocol for further details on how our lysates are prepared.
User storage instructions: Lyophilizate may be stored at 4°C. After reconstitution, store at -20°C for short-term storage or -80°C for long-term storage.
This product is subject to limited use licenses from The Broad Institute and ERS Genomics Limited, and is developed with patented technology. For full details of the limited use licenses and relevant patents please refer to our limited use license and patent pages.
What's included?
Properties and storage information
Gene name
Gene editing type
Gene editing method
Knockout validation
Zygosity
Shipped at conditions
Appropriate short-term storage conditions
Appropriate long-term storage conditions
Supplementary information
This supplementary information is collated from multiple sources and compiled automatically.
Biological function summary
Rel B serves as a critical component of the alternative NF-κB signaling pathway. It often forms a complex with another NF-κB family member called p52. This complex controls the transcription of genes involved in the immune response cell survival and differentiation. Additionally Rel B contributes to the development of secondary lymphoid organs and modulation of immune responses.
Pathways
Rel B integrates into the non-canonical NF-κB signaling pathway also influencing the canonical pathway to a lesser extent. In the non-canonical pathway Rel B interacts with NIK and p100 to influence immune cell function. This involvement makes Rel B essential in processes like adaptive immunity and inflammatory responses. The protein p52 closely associates with Rel B aiding its activity in these pathways.
Quality control
STR analysis
CSF1PO, D13S317, D7S820, D5S818, TH01, D16S539, TPOX
Cell culture
Biosafety level
EU: 2 US: 2
Adherent/suspension
Adherent
Gender
Female
Complementary Products
Primary Antibodies
AB309085
Anti-Rel B antibody [EPR26077-23] - BSA and Azide free
RabMAb|Recombinant
![Western blot - Anti-Rel B antibody [EPR26077-23] - BSA and Azide free (AB309085)](https://content.abcam.com/products/images/rel-b-antibody-epr26077-23-bsa-and-azide-free-ab309085--western-blot-img409598.jpg)
- 0
- 0
Product promise
Please note: All products are 'FOR RESEARCH USE ONLY. NOT FOR USE IN DIAGNOSTIC OR THERAPEUTIC PROCEDURES'.
For licensing inquiries, please contact partnerships@abcam.com